Muparfostat (PI-88) is a mixture of highly sulfated, monophosphorylated mannose oligosaccharides, derived from the extracellular phosphomannan of the yeast Pichia (Hansenula) holstii, with potential antiangiogenic activity.
- Mechanism
- Curator reviewed
PI-88 retards the growth of primary tumours by inhibiting new blood vessel growth (angiogenesis) in two ways: Heparan sulfate mimicry causes inhibition of heparanase, which prevents the release of angiogenic growth factors from the extracellular matrix (ECM). Interaction with angiogenic growth factors VEGF (Vascular Endothelial Growth Factor), FGF-1 (Fibroblast Growth Factor -1) and FGF-2, reduces their functional activity. PI-88 binds with high (nanomolar) affinity to these growth factors.
- Primary indication
- Investigated for use/treatment in hepatocellular carcinoma, liver cancer, melanoma, and multiple myeloma.Curator reviewed
- Formula / weight
- C18H33O49PS10 · 1384.99 g/mol (avg)
- Also known as
- Heparanase inhibitor PI-88 · Mannopentaose phosphate sulfate · Phosphomannopentaose sulfate · Sulfated mannopentaose phosphate
Resolves to
RIYITPRTNFEGIA-UHFFFAOYSA-NSMILESOP(O)(=O)OCC1OC(OC2C(OS(O)(=O)=O)C(COS(O)(=O)=O)OC(OC3C(OS(O)(=O)=O)OC(COS(O)(=O)=O)C(OS(O)(=O)=O)C3OS(O)(=O)=O)C2OS(O)(=O)=O)C(OS(O)(=O)=O)C(OS(O)(=O)=O)C1OS(O)(=O)=OWhat you can answer from here — as of September 12, 2026
Which drugs share a target with Muparfostat, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account